TG Therapeutics Stock News

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

The stock price of TG Therapeutics (NASDAQ: TGTX), a commercial stage biopharmaceutical company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases, has seen

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

TG Therapeutics Inc (TGTX) shares closed this week 40.9% lower than it did at the end of last week. The stock is currently down 56.5% year-to-date, down 82.2% over the past 12 months, and up 74.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.6%, and the S&P 500 fell 3.5%. Trading Activity Shares traded as high as $15.26 and as low as $8.04 this week.Trading volume this week was 321.4% higher than the 10-day average and 584.3% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 175.7% The company's stock price performance over the past 12 months lags the peer average by 192.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

TGTX stock down 40% after CEO discloses partial clinical hold at B. Riley chat yesterday.

Check out these penny stocks insiders are buying Losers ION Geophysical Corporation (NYSE: IO ) shares fell 53.6% to settle at $0.51 on Thursday. Epizyme, Inc. (NASDAQ: EPZM ) shares dipped 44.2% to close at $1.06 on Thursday after the company priced an underwritten public offering of 56,666,667 shares at $1.50 per share, before underwriting discounts. TG Therapeutics, Inc. (NASDAQ: TGTX ) dropped 40.5% to settle at $8.27 on Thursday. TG Therapeutics said the FDA imposed partial clinical hold on select studies of U2 and its components for CLL and NHL. Cyngn Inc. (NASDAQ: CYN ) tumbled 35.7% to close at $1.62. PetVivo Holdings, Inc. (NASDAQ: PETV ) fell 35% to close at $1.30. PetVivo recently announced distribution of its veterinary medical device, SPRYNG, by Vetcove, Inc. Advanced Human Imaging Limited (NASDAQ: AHI ) fell 33.8% to settle at $1.82. Advanced Human Imaging recently signed partnership with Activate Health OÜ. Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) dropped 33.6% to close at $0.6280.

TG Therapeutics Inc''s (NASDAQ: TGTX ) CEO Michael Weiss said that the FDA has placed a partial clinical hold on some combination candidate studies for leukemia and lymphoma. Speaking at the B. Riley Securities'' 2022 Virtual Oncology Investor Conference, Weiss disclosed that FDA placed partial holds on studies of the U2 combination UKONIQ … Full story available on Benzinga.com

TG Therapeutics is down 30% this morning after CEO Michael Weiss said that the FDA has placed a partial clinical hold on some combination candidate studies for leukemia and lymphoma.

Fireside chat scheduled for 10:00 AM ET on Thursday, January 27, 2022 Fireside chat scheduled for 10:00 AM ET on Thursday, January 27, 2022

Fireside chat scheduled for 10:00 AM ET on Thursday, January 27, 2022 Fireside chat scheduled for 10:00 AM ET on Thursday, January 27, 2022

Bargain-hunting investors have good reason to be tempted, but a steep sell-off alone isn't enough of a bullish argument.

Bargain-hunting investors have good reason to be tempted, but a steep sell-off alone isn't enough of a bullish argument.

Presentation scheduled for Monday January 10, 2022 at 9:45 AM ET Presentation scheduled for Monday January 10, 2022 at 9:45 AM ET